Proteomic Analysis of Human Hepatocellular Carcinoma

• Sponsor: Far Eastern Memorial Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT01177631
• Collaborator: (none)
• Enrollment: 5
• Location: 1
• Duration (Months): 11
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.

Condition or Disease	Intervention/Treatment	Phase
Carcinoma, Hepatocellular	Procedure: Operation	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 5 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis
• Study Start Date: Feb 1, 2009
• Actual Primary Completion Date: Jan 1, 2010
• Actual Study Completion Date: Jan 1, 2010

Outcome Measures

Primary Outcome Measures

1. Recurrence [one year]

   Evidence of clinically definite vascular invasion of hepatocellular carcinoma. Confirmed by operation. Compare the proteomic expression of tumor, non-tumor ans tumor tissue in vascular part.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

Arm A: Hepatocellular carcinoma with vessel invasion:

• hepatocellular carcionoma, pathologic diagnosed.

• image documented vessel invasion, including portal vein thrombosis

• eligible for surgical intervension.

Arm B: hepatocellular carcinoma without vessel invasion:

• hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to EASL criteria.

• no vessel invasion on image.

Arm C: Healthy hepatitis carrier:

• patients age >18 years old with hepatitis B or C

• normal liver function.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Far Eastern Memorial Hospital	Taipei		Taiwan	220

Sponsors and Collaborators

• Far Eastern Memorial Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Meng-Tzu Weng, Physician, Far Eastern Memorial Hospital
• ClinicalTrials.gov Identifier: NCT01177631
• Other Study ID Numbers: 97068
• First Posted: Aug 9, 2010
• Last Update Posted: Feb 5, 2016
• Last Verified: Feb 1, 2016

• Keywords provided by Meng-Tzu Weng, Physician, Far Eastern Memorial Hospital: Carcinoma, hepatocellular; Portal vein; Proteomics
• Additional relevant MeSH terms: Carcinoma; Carcinoma, Hepatocellular

Study Results

No Results Posted as of Feb 5, 2016